Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M307039200 on December 31, 2003

J. Biol. Chem., Vol. 279, Issue 13, 12190-12205, March 26, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/13/12190    most recent
M307039200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossman, C. E.
Right arrow Articles by Perl, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossman, C. E.
Right arrow Articles by Perl, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ZNF143 Mediates Basal and Tissue-specific Expression of Human Transaldolase*

Craig E. Grossman{ddagger}§, Yueming Qian{ddagger}, Katalin Banki¶, and Andras Perl{ddagger}§||

From the Departments of {ddagger}Medicine, §Microbiology and Immunology, and Pathology, State University of New York, Upstate Medical University, College of Medicine, Syracuse, New York 13210

Received for publication, July 2, 2003 , and in revised form, December 31, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Transaldolase regulates redox-dependent apoptosis through controlling NADPH and ribose 5-phosphate production via the pentose phosphate pathway. The minimal promoter sufficient to drive chloramphenicol acetyltransferase reporter gene activity was mapped to nucleotides –49 to –1 relative to the transcription start site of the human transaldolase gene. DNase I footprinting with nuclear extracts of transaldolase-expressing cell lines unveiled protection of nucleotides –29 to –16. Electrophoretic mobility shift assays identified a single dominant DNA-protein complex that was abolished by consensus sequence for transcription factor ZNF143/76 or mutation of the ZNF76/143 motif within the transaldolase promoter. Mutation of an AP-2{alpha} recognition sequence, partially overlapping the ZNF143 motif, increased TAL-H promoter activity in HeLa cells, without significant impact on HepG2 cells, which do not express AP-2{alpha}. Cooperativity of ZNF143 with AP-2{alpha} was supported by supershift analysis of HeLa cells where AP-2 may act as cell type-specific repressor of TAL promoter activity. However, overexpression of full-length ZNF143, ZNF76, or dominant-negative DNA-binding domain of ZNF143 enhanced, maintained, or abolished transaldolase promoter activity, respectively, in HepG2 and HeLa cells, suggesting that ZNF143 initiates transcription from the transaldolase core promoter. ZNF143 overexpression also increased transaldolase enzyme activity. ZNF143 and transaldolase expression correlated in 21 different human tissues and were coordinately upregulated 14- and 34-fold, respectively, in lactating mammary glands compared with nonlactating ones. Chromatin immunoprecipitation studies confirm that ZNF143/73 associates with the transaldolase promoter in vivo. Thus, ZNF143 plays a key role in basal and tissue-specific expression of transaldolase and regulation of the metabolic network controlling cell survival and differentiation.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Metabolism of glucose through the pentose phosphate pathway (PPP)1 fulfills two unique functions: formation of ribose 5-phosphate for the synthesis of nucleotides, RNA and DNA; and generation of NADPH as a reducing equivalent for biosynthetic reactions. Medical importance of PPP was first appreciated when deficiencies of certain enzymes of the pathway, most often deficiency of glucose-6-phosphate dehydrogenase (G6PD), were found to be associated with hemolytic anemia (1). PPP is important in host defense mechanisms in all tissues against oxidative stress (2), in embryogenesis/morphogenesis (3), neurulation (4), myelination (5), inflammation (6–9), lymphocyte activation (10, 11), phagocytosis (7, 9), cardiac arrhythmias (12), radiation resistance of malignant tumors (13), and toxicity of high glucose concentrations in diabetes mellitus (14–16). Many of these processes are associated with apoptosis, a fundamental form of programmed cell death (17). Apoptosis is indispensable for normal development and maintenance of homeostasis within multicellular organisms (18). Reactive oxygen species (ROS) have long been considered as toxic by-products of aerobic existence, but evidence is now accumulating that controlled levels of ROS modulate cellular function and are necessary for signal transduction pathways, including those mediating programmed cell death (19). A normal reducing atmosphere, required for cellular integrity is provided by reduced GSH that protects cells from damage by ROS (2). Regeneration of GSH from its oxidized form, GSSG, is dependent on NADPH produced by the PPP (2).

Understanding how the PPP is regulated has been complicated by the fact that the pathway is composed of two separate phases, oxidative and nonoxidative. Reactions in the oxidative phase are irreversible, whereas all reactions of the nonoxidative phase are fully reversible. Nevertheless, the two phases are functionally connected. The nonoxidative phase can convert ribose 5-phosphate into glucose 6-phosphate for the oxidative phase, and thus, indirectly, it can also contribute to generation of NADPH (20). The rate-limiting enzymes for the two phases are different. The oxidative phase is primarily dependent on G6PD (21). Although the control of the nonoxidative branch is less well established, transaldolase (TAL) has been proposed as its rate-limiting enzyme (21, 22).

TAL catalyzes the transfer of a 3-carbon fragment, corresponding to dihydroxyacetone, to D-glyceraldehyde 3-phosphate, D-erythrose 4-phosphate, and a variety of other acceptor aldehydes, including nonphosphorylated trioses and tetroses. Enzymatic activity of TAL is regulated in a tissue-specific (21–28) and developmentally specific manner (4, 29). In the brain, TAL is expressed selectively in oligodendrocytes at high levels (28). This is particularly interesting because myelin sheaths are formed by oligodendrocytes, and lesions in the most common demyelinating disease of the central nervous system, multiple sclerosis, are characterized by a progressive loss of oligodendrocytes and demyelination (30). High levels of TAL expression in oligodendrocytes may be related to synthesis of lipids as major constituents of myelin and exquisite susceptibility of these cells to damage by reactive oxygen species, nitric oxide, and tumor necrosis factor {alpha} released by activated macrophages and astrocytes (31).

Data from this laboratory have provided evidence that TAL can regulate susceptibility to apoptosis through control of the balance between the two branches of the PPP and its overall output as measured by NADPH and GSH production (32). Overexpression of TAL in Jurkat and H9 human T cell lines results in a decrease in G6PD and 6-phosphogluconate dehydrogenase activities and NADPH and GSH levels and renders the cell highly susceptible to apoptosis induced by serum deprivation, H2O2, nitric oxide, tumor necrosis factor {alpha}, Fas antibody, or infection by human immunodeficiency virus, type 1 (32–34). In addition, reduced levels of TAL results in increased G6PD and 6-phosphogluconate dehydrogenase activities and increased GSH levels with inhibition of apoptosis. Disruption of the mitochondrial transmembrane potential ({Delta}{psi}m), the point of no return in the effector phase of programmed cell death (35, 36), is subject to regulation by an oxidation-reduction equilibrium of ROS, pyridine nucleotides (NAD/NADH and NADP/NADPH), and GSH levels (37). The extent of Fas-induced mitochondrial ROI production, changes in {Delta}{psi}m, caspase activation, and cell death are regulated by TAL expression levels (34). The impact of TAL on apoptotic signaling (32) may be related to an overwhelming influence of TAL-catalyzed dihydroxyacetone transfer reactions on the balance between the two branches of PPP (32) that controls intracellular NADPH levels and neutralization of ROS (38). TAL-dependent changes in NADP/NADPH levels may regulate expression of G6PD through oxidative stress-response elements located in the G6PD promoter (39). Therefore, regulation of TAL expression may play a pivotal role in tissue- and cell type-specific metabolic signaling (19, 38).

TAL-H is a single copy gene located on the short arm of human chromosome 11 at p15.4–15.5 (40). The eight exons encoding a 337-amino acid protein of 37.6 kDa (41) are contained within a 17.5-kb genomic locus (TALDO1) (42). In the present study, we localized the core promoter of TAL-H to nucleotide positions (np) –49 to –1 that harbors a DNA element that is recognized and functionally activated by transcription factor ZNF143, a human homolog of Xenopus selenocysteine tRNA gene transcription activating factor (Staf) (43, 44). This is a seven-zinc finger transcription factor capable of enhancing transcription of mRNA, tRNASec, snRNA, and snRNA-type genes via RNA polymerase II or III (43–47). ZNF143 is encoded by a single copy genomic locus within a 10-megabase distance from the TAL-H locus at band p15.4 of human chromosome 11 (48). Site-directed mutagenesis of the ZNF143/76 motif abolished transcriptional activity of the core TAL-H promoter. Expression of TAL-H correlated with that of ZNF143 in 21 different human tissues and both were up-regulated in lactating mouse mammary glands as compared with nonlactating controls. Overexpression of ZNF143 enhanced TAL-H promoter activity, and a dominant-negative form of ZNF143 blocked transcription from the TAL-H promoter, indicating that ZNF143 may play a key role in regulating tissue-specific expression of TAL-H.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—HepG2 human hepatoma cells (ATCC, Manassas, VA) were cultured in minimum essential medium with Earle's salts, 10% fetal bovine serum, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B. HeLa human cervix carcinoma cells (from ATCC) and MO3.13 human oligodendroglioma cells (kindly provided by Dr. Neil Cashman, Montreal Neurological Institute, Montreal, Canada) were grown in Dulbecco's modified Eagle's medium with 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, and 10 µg/ml amphotericin B. HOG human oligodendroglioma cells (from Dr. Glyn Dawson, University of Chicago) were maintained in Dulbecco`s modified Eagle's medium with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 units/ml penicillin, 100 µg/ml streptomycin, and 10 µg/ml amphotericin B. Jurkat human T cell leukemia cells (49) were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics. All cell lines were maintained in a humidified atmosphere with 5% CO2 at 37 °C. Cell culture products were purchased from Cellgro (Mediatech Inc., Herndon, VA).

Plasmids and Oligonucleotides—Mutagenesis of TAL-H promoter constructs were generated by PCR using the QuickChange Site-directed Mutagenesis kit as suggested by the manufacturer (Stratagene, La Jolla, CA). 25 ng of template was incubated with 125 ng of sense and antisense primers, dNTPs, and subjected to 18 PCR cycles with Pfu turbo DNA polymerase with denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min, and extension at 68 °C for 10 min. DpnI was used to digest the parental supercoiled double-stranded methylated DNA for 1 h at 37 °C. Transformations were performed in Escherichia coli XL-1 Blue cells using DpnI-treated DNA. Plasmids were prepared using Qiagen Plasmid Maxi Kit Columns (Qiagen, Valencia, CA). Introduction of mutations into the TAL-H promoter constructs were verified by DNA sequencing. AP-2 and Sp1 consensus oligonucleotides were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). TARE-6 oligonucleotide, derived from full-length TARE-6 (42), was used as a nonspecific competitor in electrophoretic mobility shift assays (EMSAs). ZNF143/76 (50) and SOX5 (51) consensus sequences were generated based on published reports. All oligonucleotides used in EMSAs and for generating TAL-H promoter-chloramphenicol acetyltransferase (CAT) reporter gene constructs were synthesized by Ransom Hill Bioscience (Ramona, CA).

Transient Transfections and Reporter Gene Assays—HepG2 cells were transfected with 1.6 µg of pBLCAT3-based (52) TAL-H promoter reporter constructs at 80% confluency in 9.5-cm2 wells using 20 µl of PLUS reagent and 4.8 µl of LipofectAMINE reagent (Invitrogen). 80% confluent HeLa cells in 3.8-cm2 wells were transfected with 0.8 µg of pBLCAT3-based TAL-H promoter vectors using 10 µl of PLUS reagent and 2.4 µl of LipofectAMINE reagent. Each cell line was cotransfected with pRSV{beta}-gal ({beta}-galactosidase reporter gene driven by the Rous sarcoma virus promoter (53)) using 1.6 µg for HepG2 and 0.8 µg for HeLa cells, respectively, in order to normalize transfection efficiency. In each transfection, the promoterless pBLCAT3 vector was used as a negative control. For overexpression of recombinant transcription factors ZNF76 and ZNF143, the corresponding expression vectors or pCAGGS empty vector (54) was cotransfected with the TAL-H promoter CAT reporter plasmids and internal control pRSV{beta}-gal using 1 µg of each plasmid, 20 µl of PLUS reagent, and 8 µl of LipofectAMINE reagent. After 41/2 h of exposure to the DNA-LipofectAMINE complex in serum- and antibiotic-free media, the DNA complex was removed, and cells were further cultured for 36 h in complete growth media. Cells were harvested in 150 µl of 250 mM Tris, pH 7.8, and solubilized by 3 rounds of freezing and thawing. For {beta}-galactosidase assay, 30 µl of lysate was incubated with 270 µl of reaction mixture (1 mM MgCl2, 50 mM {beta}-mercaptoethanol, 3 mM o-nitrophenyl {beta}-D-galactopyranoside, and 0.1 M NaPi, pH 7.5) at 37 °C and terminated with the addition of 500 µl of 1 M Na2CO3 once the reaction turned yellow. Absorbance values were measured at 420 nm and employed to adjust the quantity of cell lysates to be used in the CAT assay for normalization of transfection efficiencies. Prior to CAT assay, lysates were heated to 65 °C for 10 min to deactivate acetylases. CAT assays were performed at 37 °C in a 50-µl reaction mixture with normalized volumes of cell lysates in 250 mM Tris, pH 7.8, 0.4 mM acetyl coenzyme A, and 0.025 µCi of [14C]chloramphenicol. Acetylated chloramphenicol was extracted with ethyl acetate and dried in a vacuum centrifuge. Pellets were resuspended in ethyl acetate, spotted on a silica gel TLC plate (Analtech, Newark, DE), and resolved in an equilibrated chromatography tank containing 19:1 chloroform/methanol until the solvent front approached the top of the TLC plate. A 445 SI PhosphorImager with ImageQuant software (Amersham Biosciences) was used to determine the ratio of acetylated to unacetylated [14C]chloramphenicol. All assays were conducted within the range of linearity of CAT activities with respect to incubation time, based on the {beta}-galactosidase assay. Each transfection experiment was repeated at least four times.

Preparation of Nuclear Extracts—Nuclear extracts (NE) were prepared according to a protocol described previously (55) at 4 °C. Briefly, cells in log phase were harvested, washed with cold phosphate-buffered saline, and resuspended in 1x packed cell volume of ice-cold hypotonic buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM dithiothreitol, and 10 mM leupeptin). Following a 15-min incubation on ice, the suspension was rapidly flushed eight times through a 25-gauge syringe to lyse cells. Homogenates were centrifuged at 16,000 x g, and pelleted nuclei were resuspended in 2/3x original packed cell volume of ice-cold buffer C (20 mM HEPES, pH 7.9, 20% glycerol, 550 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, 1 mM dithiothreitol, and 10 mM leupeptin). After constant stirring for 30 min, samples were centrifuged for 5 min at 16,000 x g, and the supernatant containing nuclear proteins was aliquoted and stored at –80 °C. Protein concentrations were determined by the Bradford method using the Bio-Rad Protein Assay (Bio-Rad).

DNase I Footprinting—DNase I footprinting was carried out with modifications of an established protocol (56, 57). Briefly, a doublestranded gel-purified TAL-H promoter DNA fragment (np –153 to +52) from a BamHI-TaqI digestion of clone 1994 (Fig. 3) was end-labeled by incorporating 3000 Ci/mmol [{alpha}-32P]dCTP (ICN Biomedicals, Aurora, OH) into the 3'-end of the sense strand using Sequenase version 2.0 DNA polymerase (U. S. Biochemical Corp.) and purified through a Sephadex G-25 spin column (Shelton Scientific, Shelton, CT). Binding reactions were conducted in 50 µl of EMSA binding buffer (see below) without bovine serum albumin incubating 0.035 pmol (65,000–80,000 cpm) of TAL-H promoter probe with 40 µg of NE for 10 min at room temperature. Then the reaction was supplemented with 50 µl of 5 mM CaCl2, 10 mM MgCl2 and allowed to equilibrate for an additional minute at room temperature. Subsequently, the mixture was treated with 1.5 units of DNase I (Promega, Madison, WI) for 1 min at room temperature and terminated with the addition of 90 µl of 30 mM EDTA. Nuclear proteins were digested with 25 µg of proteinase K for 10 min at room temperature. After phenol/chloroform extraction, the aqueous phase was ethanol-precipitated overnight with 30 µg of GlycoBlue (Ambion, Inc., Austin, TX). The DNA pellet was resuspended in 5 µl of 1:2 diluted loading dye (U. S. Biochemical Corp. Stop Solution: 95% formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.05% xylene cyanol FF), denatured at 95 °C for 5 min, and separated on a 6% polyacrylamide, 8 M urea sequencing gel run at 65 watts in 1x Tris borate/EDTA (TBE) buffer. The gel was fixed in 10% methanol, 10% acetic acid for 30 min, dried under vacuum at 80 °C for 1 h, and subjected to autoradiography at –80 °C with an intensifying screen. Control reaction consisted of 0.035 pmol of probe incubated with 0.75 units of DNase I in the absence of nuclear extract. Identification of the location of the protected regions within the TAL-H promoter was determined by alignment with a 35S-labeled sequencing ladder run alongside the footprinting reactions.



View larger version (38K):
[in this window]
[in a new window]
  		FIG. 3.
Localization of putative transcription factor-binding sites within the 5' BamHI-TaqI TAL-H promoter fragment. Nucleotide positions are numbered relative to the start site of transcription (+1, indicated by arrow). Boxes correspond to footprinted regions (shown in Fig. 2). Putative cis-acting DNA recognition elements (60) overlapping the sense or antisense strand of the footprinted regions are marked above or below the sequence, respectively. Asterisk indicates ATG translation start site of TAL-H.

 
Electrophoretic Mobility Shift Assay—Double-stranded synthetic oligonucleotides (Fig. 4) were generated by heating primer pairs to 95 °C for 5 min in 100 mM NaCl, 10 mM Tris, pH 8, 1 mM EDTA, and slowly cooling to room temperature. These double-stranded oligonucleotides were 5'-end-labeled with 4,500 Ci/mmol [{gamma}-32P]ATP (ICN Biomedicals) and T4 polynucleotide kinase (New England Biolabs, Beverly, MA) for 1 h at 37 °C and purified on Sephadex G-25 spin columns for use as EMSA probes. 10 µg of NE was incubated with 20 fmol (45,000–60,000 cpm) of double-stranded probe in EMSA binding buffer (20 mM Tris, pH 7.6, 50 mM NaCl, 1 mM MgCl2, 0.2 mM EDTA, 5% glycerol, 1 µg of poly(dI-dC)·poly(dI-dC), 30 µg of bovine serum albumin, 0.1 mM PMSF, and 0.5 mM dithiothreitol) for 30 min at room temperature in a total volume of 20 µl in the presence or absence of 200-fold molar excess cold competitor DNA. In supershift experiments using transcription factor-specific antibodies, 2 µl of ZNF N-terminal or C-terminal anti-ZNF143/76 peptide polyclonal rabbit antibodies (Abs), kindly provided by P. Carbon (58), Sp1 or AP-2{alpha} rabbit polyclonal peptide Abs (Santa Cruz Biotechnology), or TAL-H-specific polyclonal rabbit Ab 170 (41) was preincubated with NE in EMSA binding buffer for 30 min followed by a 30-min incubation with the 32P-labeled probe at room temperature. DNA-protein complexes were resolved on a pre-run 7% (29:1 acrylamide/bisacrylamide) polyacrylamide gel run at 10 mA in 0.4x TBE; supershift experiments were electrophoresed in a 6% pre-run (29:1 acrylamide/bisacrylamide) polyacrylamide gel run at 29 mA in 0.4x TBE. Following electrophoresis, gels were dried under vacuum at 80 °C for 1 h and subjected to autoradiography. The intensities of shifted protein-DNA complexes were quantified using PhosphorImager analysis.



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 4.
Sequences of doublestranded oligonucleotides utilized in EMSAs. TAL-H_P12 corresponds to nucleotides –41 to –4 of the wild-type TAL-H promoter. Recognition motifs for SOX5, ZNF143/76, AP-2, and Sp1 are boxed within TAL-H_P12. Three partially overlapping AP-2 motifs were noted within nucleotides –41 to –4. TAL-H_SOXmut and TAL-H_ZNFmut doublestranded oligonucleotides contain mutations within the TAL-H np –41 to –4 promoter (boldface lowercase nucleotides) critical for binding to the SOX5 or ZNF143/76 motifs, respectively. SOX consensus, ZNF consensus, AP-2 consensus, and Sp1 consensus double-stranded oligonucleotides contain consensus binding motifs for SOX-5, ZNF143/76, AP-2, and Sp1 (boxed and boldface), respectively. Nonspecific competitor DNA was derived from TARE-6 (42).

 
Western Blot Analysis—Whole tissue extracts were prepared by mechanically grinding freshly excised tissue in 300 µl of buffer containing 50 mM Tris, pH 7.5, 100 mM NaCl, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100, 1 mM PMSF, 2 µg/ml aprotinin, 0.1 mM leupeptin, 1 mM sodium orthovanadate, 0.1 mM sodium molybdate, 10 mM sodium pyrophosphate, and 50 mM NaF for 20 –30 s on dry ice. Protein content was quantified using the Bradford method. 20 µg of protein lysates were separated on a 12% SDS-polyacrylamide gel and immunoblotted with ZNF C-terminal Ab (2 h, 1:1,000), TAL-H Ab 170 (overnight, 1:1,000), and {beta}-actin-specific mouse Ab 1501R (overnight, 1:3,000, Chemicon International, Temecula, CA) that had been previously treated overnight with blocking reagents according to previous methods (41). Horseradish peroxidase-conjugated goat anti-rabbit IgG (1 h, 1:10,000 or 1:5,000 (Chemicon)) was utilized as a secondary Ab for ZNF C-terminal or TAL Abs, respectively, whereas biotin-conjugated goat anti-mouse IgG (1 h, 1:1,000, Chemicon) and streptavidin (1 h, 1:1,000, Chemicon) were used as secondary and tertiary Abs, respectively, for detection of {beta}-actin. A polyclonal rabbit antibody to G6PD (59) at a dilution of 1:5,000 for 2 h, followed by a 1-h incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5,000), was employed for assessment of G6PD levels in mouse mammary tissue. Expression of ZNF143 and ZNF76 was visualized by enhanced chemiluminescence (Western Lightning Chemiluminescence Reagent Plus, PerkinElmer Life Sciences), followed by detection of TAL and {beta}-actin using 4-chloronaphthol. Automated densitometry was utilized for quantifying the relative levels of protein expression using a Kodak Image Station 440CF with Kodak One-dimensional Image Analysis software (Eastman Kodak Co.).

Chromatin Immunoprecipitation (ChIP) Assay—In vivo binding of transcription factor ZNF143/76 to the human (TAL-H) and mouse transaldolase (TAL-M) promoter was investigated using the ChIP assay according to the protocol of Upstate Biotechnology, Inc. (Lake Placid, NY). Briefly, human cell monolayers or minced mouse mammary gland tissue was treated with 1% formaldehyde in tissue culture medium for 10 min at 37 °C. Cell or tissue samples were washed twice in ice-cold phosphate-buffered saline containing protease inhibitors (1 mM PMSF, 1 µg/ml aprotinin, and 1 µg/ml pepstatin A). Cells were pelleted and lysed in SDS Lysis Buffer (Upstate Biotechnology Inc.). Samples were sonicated to shear DNA to lengths between 200 and 1000 bp. Subsequently, an aliquot of sheared DNA was analyzed by agarose gel electrophoresis to confirm sheared DNA length and standardize protein-DNA complex input for immunoprecipitation. The chromatin samples were incubated overnight at 4 °C with rabbit antibody directed to the C terminus of ZNF143/76 (termed ZNF C-terminal, kindly provided by P. Carbon) (58). Rabbit antibody 170 specific for TAL-H (41) was used as a negative control. Immune complexes were precipitated with salmon sperm DNA-bovine serum albumin-Sepharose beads. DNA was prepared by treatment with DNase- and RNase-free proteinase K, extraction with phenol and chloroform, and ethanol precipitation. PCR was performed with primers flanking the ZNF143/76-binding sites in the TAL-H and TAL-M promoters, respectively. A 194-bp TAL-H promoter fragment was detected with sense and antisense primers corresponding to nucleotide positions –115 -> –94 (Fig. 3) and 78 -> 61 (5'-CCTCTGACGCTTCACGGG-3'). As TAL-H control region, sense (5'-CGTCCTGGGGAATTACAGGG-3') and antisense primers (5'-AAGGCCAACTAGACTAGCACGAGGG-3') flanking a 270-bp genomic fragment (base positions 8357 -> 8603; GenBankTM accession number AF058913 [GenBank] ) were utilized. A 201-bp TAL-M promoter fragment was detected with sense (5'-GGCAAGGTCTCCAAGTACATGG-3') and antisense primers (5'-GGTGGTGAACTGCTTGAGCTGG-3') corresponding to nucleotide positions –111 -> 89 with respect to the ATG codon of TAL-M (GenBankTM accession number Hsu67611gb_pr). As TAL-M control region, sense (5'-CGTCCTGGGGAATTACAGGG-3') and antisense primers (5'-AAGGCCAACTAGACTAGCACGAGGG-3') flanking a 217-bp genomic fragment, located ~4 kb upstream from the first ATG codon, were utilized.

Statistical Analysis—Statistical analyses were performed with Prism version 3.0 for Windows (GraphPad Software, San Diego). CAT activities of different constructs were compared with Student's t test. Correlation of ZNF143, ZNF76, and TAL expression in human postmortem tissues were analyzed by linear regression. Data were expressed as the means ± S.E. of individual experiments. Changes were considered significant at a p value < 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Cloning of the TAL-H Promoter Region—The human transaldolase (TAL-H) genomic locus was cloned from a {lambda} DASH genomic library of human peripheral blood lymphocytes (42). Based on comparative sequence analysis of the genomic locus (GenBankTM accession numbers AF058913 [GenBank] and NT_035113 [GenBank] ) and seven human TAL cDNA clones as well as primer extension studies, the transcription start site was mapped 48 bases upstream from the ATG codon of our original cDNA clone (GenBankTM accession number L19437 [GenBank] ). As described previously, the TAL-H locus is transcribed into a single 1.3-kb mRNA (42).

Functional Mapping of the TAL-H Minimal Promoter to np –49 to –1—In order to delineate the promoter of the TAL-H gene, a 2.7-kb genomic DNA fragment, flanked by 5' PstI and 3' TaqI sites with the latter located at nucleotide position +52 with respect to the transcriptional start site, was cloned into the pBLCAT3 reporter plasmid (52) immediately upstream of the chloramphenicol acetyltransferase (CAT) reporter gene. A 955-base-long TaqI fragment, nucleotides –903 to +52 contained in construct 1357 (Fig. 1), was sequenced previously (GenBankTM accession number AF058912 [GenBank] ) along with the 17,479-nucleotide-long genomic locus harboring all eight coding exons of TAL-H (GenBankTM accession number AF058913 [GenBank] ). 5' deletions of this upstream TAL-H genomic DNA were created, and the resulting constructs were tested for promoter activity by transient transfection of HepG2 and HeLa cell lines (Fig. 1), which endogenously express TAL-H. The {beta}-galactosidase reporter gene driven by the Rous sarcoma virus promoter, pRSV{beta}-GAL (53), was cotransfected with each promoter construct in order to normalize transfection efficiency. The promoterless pBLCAT3 vector was used as a negative control in each transfection. Promoter strength was computed relative to the construct containing nucleotides –153 to +52 (1994 = 100%; Fig. 1). 5' serial deletions from –2.7 kb to –154 did not eliminate promoter activity in either cell line, implying that the basal promoter was contained within a 205-bp segment spanning bases –153 to +52. Decreased promoter activities were observed in constructs 2075 and 1357, suggesting the presence of negative cis-acting regulatory sequences farther upstream from the TAL-H core promoter. Removal of nucleotides –143 to –50 (6881) from this 205-bp 5' promoter had no impact on transcriptional activation in either cell line. Although deletion of bases –49 to –1 (6996) completely abrogated CAT activity in HepG2 cells, significant transcriptional activity was still retained at 35% of base line in HeLa cells (p < 0.0001).



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 1.
Deletion mapping of TAL-H promoter activity within a 2.7-kb DNA upstream element based on CAT reporter gene assays. Left panel, physical maps of pBLCAT3-based constructs containing upstream DNA segments serially deleted from the 5'-end. Nucleotide positions of promoter DNA sequences are designated relative to the transcription start site of TAL-H (+1, represented by an arrow). BamHI (B), PstI (P), and TaqI (T) restriction sites within the TAL-H promoter sequence are shown as landmarks. Shaded boxes indicate the promoter sequence retained in each construct, whereas deleted portions ({Delta}) are denoted by flanking nucleotide residues. Maps of constructs 1994, 6863, 6886, 6881, and 6996 are magnified for visual clarity. pBLCAT3-based TAL-H promoter-CAT reporter constructs, with corresponding names shown on the left-hand side, were transiently transfected into HepG2 and HeLa cells, using pBLCAT3 and pRSVCAT as negative and positive controls, respectively, in all experiments. Each plasmid was cotransfected together with the pRSV{beta}-gal expression vector to standardize for transfection efficiency. A representative transfection of HepG2 cells is shown in the bottom inset. Right panel, transcriptional activities relative to construct 1994 composed of nucleotides –153 to +52 (100%, open bar) are displayed as bar charts. Data represent mean ± S.E. of at least 18 experiments. Significant differences in CAT activity relative to construct 1994, defined as p < 0.05 (*) or p < 0.001 (***), are shown for each promoter segment.

 
Reduction of the promoter element to np –49 to –1 (6886) was sufficient to drive basal transcription in both HepG2 and HeLa cells, albeit at lower levels than the intact 205-bp promoter element. In the antisense orientation, none of the TAL-H DNA fragments initiated CAT activity (data not shown). Taken together, these observations indicate that a 49-nucleotide region immediately upstream from the transcriptional start site contains the core sequence required for basal TAL-H transcription. Furthermore, because nucleotides +1 to +52 only yielded promoter activity in HeLa but not HepG2 cells, it is possible that a DNA element(s) within this region may mediate tissue-specific regulation of TAL-H gene expression. Transfections conducted in Jurkat human T cells paralleled the results observed in HeLa cells (data not shown).

DNase I Footprinting of the cis-Acting DNA Element of the TAL-H Promoter—To delineate precisely the cis-acting DNA element(s) mediating basal transcription of TAL-H, DNase I footprinting was employed using NE from HeLa, HOG, MO3.13, Jurkat, and HepG2 cell lines. A 3'-end radiolabeled DNA fragment harboring nucleotides –153 to +52 was assessed for the presence of putative transcription factor-binding sites. Two footprinted regions, –29 to –16 and –102 to –89, were unveiled in all cell lines tested (Fig. 2). Protection of nucleotides –29 to –16 was consistent with CAT assay data, thus mapping a functional core promoter within residues –49 to –1 of the TAL-H gene. Whereas protection by HeLa, HOG, and HepG2 NE was confined to np –29 to –16, MO3.13 and Jurkat NE also protected nucleotides –15 to –14 (Fig. 2). Jurkat cells displayed the most variability, with additional footprints at bases –1 to +3, –12 to –6, –51 to –35, and –64 to –55. Similar protection patterns were generated by all NEs with the 205-bp probe labeled at the opposite end (data not shown). Although the protected nucleotides –102 to –89 were not necessary for basal promoter activity (Fig. 1), this region could be involved in modulating TAL-H gene expression. DNase I footprinting also revealed protection at nucleotides +12 to +45 (not shown), which may play a role in tissue- or cell type-specific promoter activity in HeLa cells (Fig. 1).



View larger version (46K):
[in this window]
[in a new window]
  		FIG. 2.
DNase I footprinting analysis of the TAL-H promoter. DNase I protection was performed with 0.035 pmol of a 205-bp BamHI-TaqI probe (–153 to +52) end-labeled at the 3'-end of the sense strand and 40 µg of NE. Control lane represents the DNase I cleavage pattern in the absence of NE. Open boxes depict regions (marked with flanking nucleotide positions) protected by each NE based on alignment with a sequence ladder. As landmarks, nucleotide positions –153, +10, and the transcription start site +1 are shown.

 
Cell Type-specific Recognition of ZNF143/76 and AP-2-binding Motifs of the TAL-H Core Promoter—Mapping potential transcription factor-binding sites within the protected region of np –29 to –16 using the TRANSFAC data base (60) revealed the presence of binding motifs for transcription factors AP-2, Sp1, SOX5 (SRY-related HMG box 5), and Staf (selenocysteine tRNA gene transcription activating factors; Zinc Finger 143 (ZNF143) and/or 76 (ZNF76); Fig. 3). Binding of transcription factor(s) to this core promoter region was assessed by EMSAs, using an oligonucleotide probe spanning np –41 to –4 (TAL-H_P12, Fig. 4). A single dominant shifted DNA-protein complex was detected with all NE (Fig. 5, A, B, D, and E, and Fig. 6, A–C). By using HepG2 cell NE, formation of this sequencespecific complex was completely abrogated with 200-fold molar excess of cold TAL-H_P12 probe, although it remained unaltered in the presence of excess cold nonspecific competitor sequence (derived from TARE-6 (42)) (Fig. 5A). A 200-fold molar excess of cold double-stranded oligonucleotides containing Sp1, SOX5, or AP-2 consensus sequences did not significantly affect formation of the shifted complex with the TAL-H probe TAL-H_P12 (Fig. 5, A, B, D, and E). By contrast, a 200-fold excess of cold ZNF143/76 consensus sequence (Fig. 4) (50) completely abolished the complex formed by the TAL-H_P12 probe using HepG2 NE (Fig. 5, A and B, and Fig. 6, A and C). The ZNF143/76 consensus sequence also profoundly, but not entirely, quenched the shifted complex formed between the TAL-H_P12 probe and HeLa NE (~5% residual activity; Figs. 5, D and E, and 6B). This residual complex was eliminated by a combination of excess cold ZNF143/76 and AP-2 consensus sequences (Figs. 5E and 6B). Combination of excess cold AP-2 and Sp1 or ZNF143/76 and Sp1 consensus sequences did not affect the complex shifted by the TAL-H_P12 (Fig. 5, B and E). In turn, complexes formed between ZNF143/76 consensus sequence and HepG2 (Fig. 5C) or HeLa NE (Fig. 5F) was completely eliminated by TAL-H_P12, further supporting a critical role of ZNF143/76 in recognition of the TAL-H promoter.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 5.
EMSAs of in vitro binding by HepG2 and HeLa NEs to the TAL-H core promoter (np –41 to –4). Binding of 10 µg of HepG2 (A–C) or HeLa NE (D–F) to 20 fmol of 32P-labeled TAL-H_P12 probe (A, B, D, and E) or ZNF consensus probe (C and F) was assessed in EMSAs. + indicates presence of NE, whereas minus] indicates control reactions without NE. Competitions were carried out with 200x molar excess of the indicated cold competitor. Sequences of the oligonucleotides employed are shown in Fig. 4.

 



View larger version (46K):
[in this window]
[in a new window]
  		FIG. 6.
Effect of ZNF143/76 and AP-2{alpha}-specific antibodies on formation of complexes between the TAL-H core promoter and HepG2 (A and C) and HeLa NE (B). 20 fmol of 32P-labeled double-stranded probes TAL-H_ZNFmut (A) and TAL-H_P12 (A–C) were assayed with 10 µg of NE in the presence or absence of antibodies specific for AP-2{alpha} or the N or C terminus of ZNF143/76 (labeled as ZNF N-terminal Ab and ZNF C-terminal Ab, respectively). As control competitors, 200x molar excess of the indicated cold oligonucleotides were utilized. Presence or absence of NE is indicated as + or –, respectively.

 
Involvement of the ZNF143/76 motif was further examined by mutagenesis of the TAL-H promoter sequence (TAL-H_ZNFmut, Fig. 4) at residues critical for transcription factor binding (50, 61). A 200-fold molar excess of TAL-H_ZNFmut, containing a substitution of five nucleotides within the ZNF143/76 motif, failed to eliminate the shifted complex formed by TAL-H_P12 (Figs. 5, A and D, and 6A) or ZNF consensus (Fig. 5, C and F) with HepG2 and HeLa NE, thus suggesting the following: 1) involvement of the ZNF143/76 motif in binding to TAL-H_P12, and 2) efficacy of the introduced mutations. Mutation of the SOX-5 motif within TAL-H_P12 (TAL-H_SOXmut, Fig. 4), which partially overlaps with the ZNF143/76 motif, did not fully eliminate competition with TAL-H_P12 (Fig. 5, A and D) or ZNF143/76 (Fig. 5, C and F) probes, arguing against involvement of SOX-5. In parallel, the ZNF143/76 consensus motif markedly inhibited formation of complexes with the TAL-H_P12 (Fig. 5, A, B, D, and E) or ZNF consensus (Fig. 5, C and F) probes using HepG2 or HeLa NE, indicating a highly specific and dominant role for the ZNF143/76 motif within the TAL-H minimal promoter (Fig. 5).

The profound but incomplete blocking by ZNF143/76 consensus of the shifted complex produced by HeLa NE and TAL-H_P12 probe led us to further investigate cooperativity with other transcription factors. Excess AP-2 consensus sequence alone only marginally diminished the shifted complex formed with HeLa NE (Fig. 6B). Combination of ZNF143/76 and AP-2 consensus sequences as cold competitors fully abrogated the shifted complex formed in the presence of HeLa NE and TAL-H_P12 probe (Figs. 5E and 6B). Combination of Sp1 with the ZNF143/76 consensus sequence was a less effective competitor than the combination of AP-2 and ZNF143/76 consensus sequences (Figs. 5E and 6B).

To characterize further the DNA-protein complex generated with np –41 to –4 of the TAL-H promoter, polyclonal antibodies to transcription factors AP-2{alpha}, Sp1, and anti-peptide antibodies to the N or C terminus of ZNF143 and ZNF76 (termed ZNF N-terminal or ZNF C-terminal, kindly provided by P. Carbon (58)) were utilized in supershift assays. Both the N and C terminus-specific ZNF143/76 antibodies markedly retarded migration of the DNA-protein complex formed with the TAL-H_P12 probe and HepG2 (Fig. 6, A and C) or HeLa NE (Fig. 6B), respectively. As a negative control, a polyclonal antibody directed against the TAL-H protein failed to alter the migratory pattern of the DNA-protein complex (Fig. 6). Antibody to AP-2{alpha} reduced formation of the TAL-H_P12-HeLa NE complex and further modified migration of the TAL-H_P12 DNA-protein complex supershifted with a ZNF143/76-specific antibody (Fig. 6B). These results demonstrated that the ZNF143/76 motif within np –41 to –4 of the TAL-H promoter is recognized by the transcription factors ZNF143 and/or ZNF76 in both HepG2 and HeLa cells, alone or in combination with AP-2{alpha} (only in HeLa), respectively.

Site-directed Mutagenesis of the ZNF143/76 Motif Abrogates TAL-H Promoter Activity—The ability of a transcription factor to interact with a DNA element in vitro may not confer promoter activity in vivo. Therefore, to assess a functional role for ZNF143 and/or ZNF76 in mediating transcription of TAL-H, the ZNF143/76 motif was mutated through substitution of five nucleotides at np –18 to –15 and np –13 within all TAL-H promoter CAT reporter gene constructs. These mutations were identical to those within the TAL-H_ZNFmut oligonucleotide (Fig. 4), which was rendered incapable of competing for NE proteins bound to the wild-type TAL-H np –41 to –4 probe (Figs. 5, A and D, and 6A) or ZNF consensus in EMSAs (Figs. 5, C and F, and 6A). Certain critical residues previously found crucial for the binding affinity of ZNF143/76 (45, 50, 62) were not mutated in the TAL-H promoter, because doing so would have also resulted in mutation of the overlapping SOX5 and AP-2 motifs. To ensure that this mutation was potent at completely eliminating binding of ZNF143/76 to the TAL-H promoter, EMSA analysis was conducted with the TAL-H_ZNFmut probe. Surprisingly, two specific complexes were formed, albeit of weak intensity, that exhibited both a faster and slower migratory pattern compared with the ZNF143/76 DNA-protein complex generated with the wild-type probe (Fig. 6A). We realize that a new recognition motif, of rather low affinity, may have been created. Data base analysis of putative proteins that may recognize this mutant promoter include AP-2, myeloid zinc finger 1 (MZF1), and Ikaros-2 (Ik-2) (60). However, the TAL-H_ZNFmut complex did not contain ZNF143/76 because of the following: 1) excess ZNF143/76 consensus sequence was incapable of competing out the shifted bands, and 2) ZNF143/76-specific antibodies did not alter the migration of these DNA-protein complexes (Fig. 6A). This indicated that the ZNF143/76 motif had been destroyed and thus could be effectively used in reporter assays. As shown in Fig. 7A, such substitutions in the ZNF143/76 recognition motif abolished CAT activity of all TAL promoter constructs in both HepG2 and HeLa cells, providing functional evidence for involvement of ZNF143/76 in initiation of TAL-H transcription. Background activity of the promoterless pBLCAT3 vector was somewhat higher in HeLa as compared with HepG2 cells (Figs. 1 and 7A), which may account for the apparent residual CAT activity observed in HeLa cells in accordance with earlier data (52). Furthermore, site-directed mutagenesis of critical AP-2 residues enhanced TAL promoter activity in HeLa cells by 20 ± 7.3% (construct 7110; p = 0.021), 28 ± 9.8% (construct 7158; p = 0.027), and 42 ± 12.3% (construct 7150; p = 0.011), respectively (Fig. 7B). Mutagenesis of AP-2 sites did not, however, affect promoter activity in HepG2 cells. This was consistent with a lack of expression by AP-2{alpha} in HepG2 cells (63, 64). Substitutions of residues involved in both AP-2 and ZNF143/76 motifs in constructs 7116, 7133, and 7141 reduced CAT activities in both HeLa and HepG2 cells. These mutagenesis studies suggested that basal transcription from the core TAL-H promoter is primarily mediated by ZNF143/76, whereas AP-2 may act as a repressor in HeLa cells.



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 7.
A, effect of site-directed mutagenesis of the ZNF143/76 recognition site on TAL-H promoter activity. Mutation of five residues corresponding to those in TAL-H_ZNFmut (Fig. 4) were introduced into each TAL-promoter-CAT reporter plasmid. Left panel, shaded boxes indicate the promoter region driving CAT activity of each construct; M, represents the location of the 5-bp mutation within the ZNF143/76 recognition motif of the TAL-H promoter. Right panel shows CAT activities of promoter constructs normalized to plasmid 1994 (100%). Data represent mean ± S.E. of at least 12 independent experiments. Effect of each mutation was compared with the corresponding wild-type construct depicted by matching shaded bars. B, effect of site-directed mutagenesis of AP-2-binding residues (constructs 7110, 7150, and 7158) or AP-2- and ZNF76/143-binding residues (constructs 7116, 7133, and 7141) on CAT activityof TAL promoter constructs in HeLa and HepG2 cells. The AP-2 and ZNF143/76 recognition motifs within np –49 to –1 of the TAL-H promoter are boxed. Capital letters show wild-type nucleotides and boldface lowercase letters indicate mutated residues. CAT activities relative to construct 6886 (100%, open bar) are displayed in the bar chart in the right panel. Data represent mean ± S.E. of at least four independent experiments. Significant differences compared with wild-type sequence are defined as p < 0.05 (*), p < 0.01 (**), and p < 0.0001 (***).

 
Regulation of TAL-H Promoter Activity by Transfection of ZNF143 Expression Vectors—To delineate involvement of ZNF143 versus ZNF76 in activation of the TAL-H promoter, HepG2 cells were cotransfected with TAL-H promoter reporter constructs and pCAGGS-based expression vectors coding for full-length human ZNF143 or ZNF76 protein or the DNA-binding domain of ZNF143 that lacks the transcriptional activation domain and acts in a dominant-negative fashion (54) (Fig. 8). Promoter activity was normalized to the CAT activity exhibited by the individual TAL-H promoter constructs cotransfected with the pCAGGS mammalian expression vector alone (65). As shown in Fig. 8, transcription from all TAL-H promoter constructs was up-regulated by ZNF143, whereas unaffected by ZNF76 overexpression. As an example, CAT activity from the minimal TAL-H promoter consisting of np –49 to –1 (6886) was enhanced 3.2 ± 0.8-fold (p = 0.0081) by full-length ZNF143, whereas ZNF76 produced no significant alteration. With respect to HepG2 cells transfected with pCAGGS alone, overexpression of ZNF143 also increased TAL enzyme activity by 27.7 ± 0.7% (p < 0.01). Acting in a dominant-negative fashion, the ZNF143 DNA-binding domain eliminated transcriptional activity of all TAL-H promoter constructs. Base-line TAL enzyme activities were not affected by overexpression of dominant-negative ZNF143, which was attributed to a >4-day-long half-life of endogenously produced TAL. Similar results were obtained with HeLa cells (data not shown).



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 8.
Effect of recombinant ZNF143, ZNF76, and the dominant-negative DNA-binding domain of ZNF143 on TAL-promoter activity. HepG2 cells were cotransfected with the indicated TAL-H promoter reporter constructs (2075, 1357, 2020, 1994, and 6886) in combination with pCAGGS-based expression vectors encoding full-length human ZNF143, ZNF76, or the DNA-binding domain of ZNF143 or the pCAGGS backbone vector alone. Left panel shows map of constructs with shaded promoter regions. CAT assays were performed based on {beta}-galactosidase activity of cotransfected pRSV{beta}gal. CAT activities were normalized to controls yielded from coexpression with pCAGGS (100%, open bars). Data represent mean ± S.E. of at least four independent experiments. Statistical significance, p < 0.05 (*), p < 0.01 (**), and p < 0.0001 (***), is indicated relative to CAT activities with pCAGGS.

 
Tissue-specific Expression of ZNF143 and TAL—According to previous studies, enzymatic activity of TAL is regulated in a tissue-specific (21–28) and developmentally specific manner (4, 29, 66). Additionally, ZNF76 (67) and ZNF143 are expressed in different tissues at variable levels (43, 61). To examine the relationship between ZNF143/76 and TAL-H expression, their relative abundance was assessed by Western blot analysis of protein lysates from 21 different human postmortem tissues (Fig. 9). Relative expression of each gene product was assessed with respect to the mean of all tissues examined with setting expression levels in the ovary at 100%. Linear regression analysis revealed a striking correlation between ZNF143 and TAL levels (p = 0.0199). High ZNF143 and TAL levels were observed in the adult ovary, adult kidney, neonatal lung, adult pancreas, and adult liver, whereas their expression was relatively low in the skeletal muscle, heart, stomach, small intestine, and colon from an adult patient. With respect to ZNF143, TAL levels were low in adrenal glands suggesting involvement of additional transcriptional and post-translational factors in controlling TAL expression. ZNF76 and TAL levels did not correlate. Neither of the ZNF isoforms nor TAL correlated with {beta}-actin or G6PD levels (not shown). Similar results were obtained from analysis of tissues from three different human donors.



View larger version (57K):
[in this window]
[in a new window]
  		FIG. 9.
Comparative analysis of tissue-specific expression of human ZNF143, ZNF76, and TAL. 20 µg of total protein lysates were loaded per lane. N, neonatal; A, adult human post-mortem tissue. Expression levels of ZNF143 and ZNF76 were assessed with a polyclonal antibody to their common C terminus (ZNF C-terminal) using enhanced chemiluminescence detection. Subsequently, the same blot was developed with antibodies to TAL-H and {beta}-actin by detection with 4-chloronaphthol. Values indicate relative expression levels with respect to those in the ovary set at 100%. Since {beta}-actin is also expressed in a tissue-specific manner, it was not used as a basis for comparison. p values indicate correlation with expression of TAL-H.

 
Increased activity of PPP enzymes has been associated previously with an NADPH requirement for reductive syntheses, such as fatty acid biosynthesis in the lactating mammary tissue (2, 23, 68, 69). Elevated expression (70) and binding activity of mStaf, the mouse homolog of human ZNF143, was noted in lactating mammary tissue of the mouse (61, 70). As shown in Fig. 10, mStaf/ZNF143, TAL, and G6PD expression were increased 14.4-, 34.4-, and 13-fold, respectively, in lactating mammary tissues as compared with nonlactating ones, further supporting this tissue-specific correlation between TAL and ZNF143 expression.



View larger version (48K):
[in this window]
[in a new window]
  		FIG. 10.
Western blot analysis of ZNF143, TAL, G6PD, and {beta}-actin in lactating and post-lactating mouse mammary tissues. In each lane, 20 µg of total protein lysates from four lactating (samples 1, 3, 5, and 7) and three post-lactating tissues (samples 2, 4, and 6) was separated on a 12% SDS-polyacrylamide gel and immunoblotted with a rabbit polyclonal antibody to the C terminus of ZNF143 (ZNF C-terminal) or antibody to TAL-H, G6PD, and {beta}-actin. Values below each lane indicate relative abundance of ZNF143, TAL, and G6PD with respect to {beta}-actin using automated densitometry. p values reflect differences between lactating and nonlactating tissues as compared with Student's t test.

 
ZNF143/76 Associates with the Human and Mouse Transaldolase Promoter in Vivo—Localization of ZNF143/76 to the human TAL (TAL-H) promoter in vivo was investigated with the ChIP assay. Formaldehyde cross-linked chromatin with DNA sheared to 200 –1000 bp in length was prepared from HeLa cells and incubated with rabbit antibody directed to the C terminus of ZNF143/76, termed ZNF C-terminal, or control antibody directed to TAL-H. DNA was extracted from immunoprecipitated protein-DNA complexes and analyzed by PCR. As shown in Fig. 11A, a 194-bp TAL-H promoter fragment containing the ZNF143/76 motif was detected in chromatin selectively precipitated by ZNF C-terminal antibody. By contrast, a 270-bp genomic fragment (base positions 8357 -> 8603; GenBankTM accession number AF058913 [GenBank] ) was absent in chromatin precipitated by ZNF C-terminal antibody.



View larger version (56K):
[in this window]
[in a new window]
  		FIG. 11.
ZNF143/76 associates with the TAL-H and TAL-M promoter in vivo. A, formaldehyde cross-linked chromatin prepared from HeLa cells was incubated with rabbit antibody directed to the C terminus of ZNF143/76, termed ZNF C-terminal, or control antibody directed to TAL-H, and immunoprecipitates were analyzed by PCR. 194-bp TAL-H promoter fragment containing the ZNF143/76 motif was detected with sense and antisense primers corresponding to nucleotide positions –115 -> –94 (Fig. 3) and 78 -> 61 (5'-CCTCTGACGCTTCAC-GGG-3'). As TAL-H control region, sense (5'-CGTCCTGGGGAATTACAGGG-3') and antisense primers (5'-AAGGCCAACTAGACTAGCACGAGGG-3') flanking a 270-bp genomic fragment (base positions 8357 -> 8603; GenBankTM accession number AF058913 [GenBank] ) were utilized. Lane 1, PCR product using DNA template extracted from total chromatin before immunoprecipitation; lane 2, PCR product using DNA template extracted from chromatin immunoprecipitated with ZNF C-terminal antibody; lane 3, PCR product using negative control DNA template. B, sequence of 765 bases located upstream of the first ATG codon of TAL-M (GenBankTM accession number AY466102 [GenBank] ). The transcription start site is designated as nucleotide position +1. The first methionine codon of TAL-M (GenBankTM accession number Hsu67611gb_pr) is in boldface type. Location of ZNF143/73-binding motif is double-underlined.AnEbox at position +2 to +7 is italicized. C, formaldehyde cross-linked chromatin was prepared from nonlactating (lanes 1 and 3) and lactating mouse mammary tissues (lanes 2 and 4) and immunoprecipitated with ZNF C-terminal antibody (lanes 3 and 4). A 201-bp TAL-M promoter fragment was detected with sense (5'-GGCAAGGTCTCCAAGTACATGG-3'; underlined) and antisense primers (5'-GGTGGTGAACTGCTTGAGCTGG-3'; underlined), corresponding to nucleotide positions –111 -> 89 with respect to the transcription start site (+1). As TAL-M control region, sense (5'-CGTCCTGGGGAATTACAGGG-3') and antisense primers (5'-AAGGCCAACTAGACTAGCACGAGGG-3') flanking a 217-bp genomic fragment, located ~4 kb upstream from the first ATG codon, were utilized. Lane 1, PCR product using DNA template extracted from nonlactating mammary tissue chromatin before immunoprecipitation; lane 2, PCR product using DNA template extracted from lactating mammary tissue chromatin before immunoprecipitation; lane 3, PCR product using DNA template extracted from nonlactating mammary tissue chromatin immunoprecipitated with ZNF C-terminal antibody; lane 4, PCR product using DNA template extracted from lactating mammary tissue chromatin immunoprecipitated with ZNF C-terminal antibody; lane 5, negative control PCR reaction lacking chromatin DNA template.

 
The mouse TAL (TAL-M) genomic locus harboring all eight coding exons was cloned from a 129SvJ murine embryonic stem cell bacterial artificial chromosome library.2 To examine association of ZNF143/73 with the TAL-M promoter, a sequence of 765 bases located upstream of the first ATG codon of TAL-M was determined (GenBankTM accession number AY466102 [GenBank] ; Fig. 11B). Based on comparison with full-length cDNA clones, transcription start site was mapped to 21 bases upstream of the first ATG codon of TAL-M (GenBankTM accession number Hsu67611gb_pr). As aligned with a 951-nucleotide upstream sequence harboring the TAL-H promoter (GenBankTM accession number AF058912 [GenBank] ), remarkably, homologies were confined to 16 bases. This homologous TAL-M sequence, corresponding to nucleotides –23 -> –38 (Fig. 11B), was 100% identical with bases –10 -> –25 of the ZNF143/76-binding motif in the TAL-H promoter (Fig. 3). A 201-bp TAL-M promoter fragment corresponding to nucleotide positions –111 -> 89 was amplified from formaldehyde cross-linked chromatin immunoprecipitated with ZNF C-terminal antibody (Fig. 11C). With respect to total DNA input, detection of TAL-M promoter PCR product was increased 4.4 ± 0.5-fold (p < 0.01) from chromatin of lactating mammary tissues, with respect to nonlactating mammary tissues. A 217-bp control genomic fragment, located ~4 kb upstream from the first ATG codon, was not detectable in chromatin immunoprecipitated with ZNF C-terminal antibody.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
TAL, a rate-limiting enzyme of the PPP, has a profound impact on the balance between the two branches of the pathway and its ultimate output of NADPH and GSH (32). These findings are in agreement with a dominant role of TAL within the metabolic network that controls intracellular NADPH levels and neutralization of ROS (38). Levels of TAL expression serve as a critical determinant of tissue and cell type-specific sensitivity to apoptosis triggered by serum deprivation, hydrogen peroxide, nitric oxide, tumor necrosis factor {alpha}, anti-Fas monoclonal antibody, or infection by human immunodeficiency virus, type 1 (32–34). Therefore, regulation of TAL expression may play a pivotal role in tissue- and cell type-specific functioning of the PPP.

The present study localized the core promoter of TAL-H to np –49 to –1 which is recognized and functionally activated by transcription factor ZNF143, the human homolog of Xenopus Staf (43, 44), a seven-zinc finger transcription factor capable of enhancing basal transcription of mRNA, tRNASec, snRNA, and snRNA-type genes via RNA polymerase II or III (43–47). Unlike most transcription factor-binding motifs, ZNF143 recognizes a relatively long and restrictive consensus sequence of 21 bp, NYY(A/T)CCC(A/G)N(A/C)AT(G/C)C(A/C)YYRCRN (46, 50). The minimal TAL-H promoter has a high (78%) G/C content (Fig. 3). Unlike most G/C-rich TATA- and Inr-less genes where transcriptional initiation is under the control of Sp1 (71–76), basal expression of TAL-H is mediated through ZNF143. DNase I footprinting and EMSA analyses mapped the ZNF143-binding motif to nucleotides –26 to –6 of the TAL-H promoter. Formation of a DNA-protein complex between the TAL-H promoter and HepG2 NE was completely abolished with a ZNF143/76 consensus sequence or a mutation of the ZNF143 motif within the TAL-H promoter. Polyclonal antibodies to ZNF143 specifically recognized and supershifted this DNA-protein complex formed by the TAL-H promoter. Point mutations of the ZNF143 motif within the TAL-H promoter completely extinguished CAT activity in HeLa and HepG2 cells. In CAT assays, transcriptional activation of the TAL-H promoter was enhanced by overexpression of full-length recombinant ZNF143. In contrast, TAL promoter activity was completely abolished by cotransfection of a dominant-negative ZNF143 producing construct.

Our study provides evidence that ZNF143 is capable of interacting with additional factors, such as AP-2{alpha}, in mediating transcription from the TAL-H promoter in HeLa cells. Mutation of the AP-2{alpha} recognition sequence increased TAL-H promoter activity in HeLa cells without significant impact in HepG2 cells, which do not express AP-2{alpha} (63, 64). Cooperativity of ZNF143 with AP-2{alpha} was further supported by EMSA and supershift analysis (Fig. 6). This was conceivable because both ZNF143 (77) and AP-2{alpha} are capable of interacting with other transcription factors (73, 78–81). Whereas excess ZNF143/76 consensus oligonucleotide completely abolished the TAL-H promoter DNA-protein complex with HepG2 NE, formation of the TAL-H promoter DNA-protein complex with HeLa NE was drastically, but incompletely, reduced. Only in the presence of both excess ZNF143/76 consensus and AP-2{alpha} consensus competitor DNA was the complex completely abolished. Furthermore, antibody to AP-2{alpha} only affected mobility of the TAL-H promoter DNA-protein complex in the presence of antibody to ZNF143/76. This indicated that the ZNF143 Ab must first alter the conformation of the complex, thereby exposing hidden AP-2{alpha} epitopes that can subsequently be recognized by AP-2{alpha} Ab. These results suggested that AP-2{alpha} may have primarily complexed with ZNF143 and did not directly bind to the TAL-H promoter DNA. Our data are indicative of a protein-protein interaction in which the binding of ZNF143 may tether AP-2{alpha} to the TAL-H promoter and thereby modulate transcription of the TAL-H gene in HeLa cells.

Although we have clearly demonstrated that ZNF143 can act alone or in combination with AP-2{alpha} to initiate TAL-H expression, the DNase I protection pattern (–29 to –16), does not completely overlap with the identified ZNF143 recognition sequence at –26 to –6. This discordance may be related to the versatility of the zinc fingers of ZNF143 in binding to DNA (50). Zinc finger 1 preferentially interacts with a GCG triplet located at the 3'-end of the ZNF143 recognition motif (50, 58), which is also present within the TAL-H promoter (–25 to –23 in Fig. 3). Binding of zinc fingers 1 and 2 of ZNF143 to the antisense TAL-H promoter sequence also envelops the AP-2{alpha}-binding site. However, identical DNase I footprints observed with HepG2 and HeLa NE suggest that AP-2{alpha} does not directly bind to the TAL-H promoter. Site-directed mutagenesis of AP-2{alpha}-binding motifs up-regulated TAL-H promoter activity in HeLa but not in HepG2 cells (Fig. 7B). Thus, AP-2{alpha} may modulate ZNF143-mediated transcription in HeLa cells by acting as a repressor (73, 82, 83). The TAL-M promoter also contains an E box at positions +2 to +7 (Fig. 11B). Although E box consensus sequence was not detected in the corresponding TAL-H region, a novel E box variant in +2 to +50 of TAL-H may play a role in tissue- and cell type-specific promoter activity, as noted in HeLa cells (Fig. 1).

Enzymatic activity of TAL is regulated in a tissue-specific (21–28) and developmentally specific manner (4, 29). TAL is highly active in the thymus (22), intestinal mucosa (22), adrenal gland (23), kidney (22), and mammary tissue of lactating and pregnant mice (23). Conversely, TAL activity is particularly low in the brain (23, 25), liver (23), heart (22, 24, 25), and skeletal muscle (22, 25, 84, 85). In the brain, TAL expression is high in myelin-producing oligodendrocytes, compared with neurons and astrocytes (28). During development of the nervous system, TAL activity levels peak at the time of active myelination (86) possibly related to a greater demand of NADPH for lipid biosynthesis (5, 87). Northern blot analysis of human tissues revealed high levels of ZNF143 mRNA in the ovary, testis, and prostate (43). In the mouse, ZNF143 is highly expressed in the lung (61), ovary (43, 61), and thymus (61). Low ZNF143 mRNA levels were found in human leukocytes, colon, thymus, and spleen (43) as well as in mouse brain, liver, and kidney (61). To our knowledge, there have not been any studies on the relative expression of TAL among various tissues. Western blot analysis of 21 different freshly processed human postmortem tissues revealed a striking correlation between ZNF143 and TAL levels (p = 0.0199). The highest ZNF143 and TAL levels were observed in the ovary, kidney, and liver. ZNF76 and TAL levels did not correlate. Neither ZNF isoforms nor TAL correlated with actin or G6PD levels. Overexpression of ZNF143 enhanced TAL-H promoter activity, and a dominant-negative form of ZNF143 blocked transcription from the TAL-H promoter (Fig. 8), indicating that ZNF143 may play a key role in regulating tissue-specific expression of TAL.

ZNF143 is required for transcriptional activation of selenocysteine transfer RNA tRNASec, which mediates incorporation of selenocysteine into selenoproteins such as glutathione peroxidase (GPx) (88, 89) and type 1 thyroxine 5'-deiodinase (90). The mouse homologs of ZNF143 (m-Staf) (61), tRNASec, and GPx are up-regulated during lactogenesis in the mouse mammary gland (70). Most interesting, expression of the ZNF143-activated cytosolic chaperonin containing t-complex polypeptide 1, Ccta, is particularly elevated in FM3A mammary carcinoma cells (91). Lactation has long been associated with increased G6PD activity and NADPH requirement for lipid biosynthesis (92, 93). Indeed, ZNF143, TAL, as well as G6PD expression were up-regulated with respect to total protein or {beta}-actin content in lactating mouse mammary glands. No ZNF143/76 consensus sequence was noted in the G6PD promoter (GenBankTM accession number NM_000402 [GenBank] ) (94), further supporting the notion that expression of TAL, but not G6PD, is selectively regulated by ZNF143. ChIP analyses show that ZNF143/73 associates with the TAL promoter in vivo and ZNF143/76 occupancy of the TAL-M promoter correlates with TAL expression in lactating versus nonlactating mammary tissues. With respect to total DNA input, detection of TAL-M promoter PCR product was increased from chromatin of lactating mammary tissue, exhibiting increased ZNF143/76 and TAL expression.

It is remarkable that activity of ZNF143-regulated enzymes, GPx, neuronal nitric-oxide synthase, and TAL are connected through a requirement for GSH (GPx) and NADPH (neuronal nitric-oxide synthase) or provision of NADPH via the PPP (TAL). Because maintenance of glutathione in a reduced state is dependent on NADPH provided by the PPP, it is conceivable that ZNF143-mediated up-regulation of TAL expression may represent an arm of coordinated metabolic changes underlying mammary gland proliferation. Increased G6PD activity is likely to be mediated through its promoter responsive to oxidative stress (59, 95) and, it is associated with increased metabolic activity of rapidly proliferating cells. By contrast, expression or enzymatic activity of TAL is not altered by H2O2 or Fas stimulation (32, 49). Therefore, TAL expression may be a critical predeterminant of tissue-specific sensitivity to oxidative stress and other cell death and differentiation signals.

ZNF143 also enhances transcription of the human interferon regulatory factor-3 gene via binding to an upstream consensus sequence at –181 –163 (96), which lies outside the core promoter (97). IRF-3, which is induced in response to viral infection, increases paramyxovirus-induced apoptosis (98). ZNF143 is necessary for direct or indirect (via tRNASec) synthesis of certain pro- and anti-oxidant enzymes including neuronal nitric-oxide synthase exon 1c (99), GPx, IRF-3, and now TAL-H, all of which can regulate susceptibility to apoptosis signals (32–34). Among these genes, TAL alone appears to be dependent on ZNF143 for both basal and tissue-specific expression. Of note, both TAL-H (40) and ZNF143 have been mapped within a <10-megabase segment of the short arm of human chromosome 11 at band p15.4 (48) and a syntenic region of mouse chromosome 7, further underlying an important genetic and functional relationship between these two genes. Thus, ZNF143 and TAL may play key roles in controlling the metabolic network that regulates cell survival and differentiation.


   FOOTNOTES
 
* This work was supported in part by Grant RO1 DK49221 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed: State University of New York, College of Medicine, 750 East Adams St., Syracuse, NY 13210. Tel.: 315-464-4192; Fax: 315-464-4176; E-mail: perla{at}upstate.edu.

1 The abbreviations used are: PPP, pentose phosphate pathway; NE, nuclear extracts; Abs, antibodies; PMSF, phenylmethylsulfonyl fluoride; ChIP, chromatin immunoprecipitation; EMSAs, electrophoretic mobility shift assays; G6PD, glucose-6-phosphate dehydrogenase; ROS, reactive oxygen species; TAL, transaldolase; np, nucleotide positions; snRNA, small nuclear RNA; CAT, chloramphenicol acetyltransferase; H-TAL, human TAL; M-TAL, murine TAL; Staf, selenocysteine tRNA gene transcription activating factor; GPx, glutathione peroxidase. Back

2 A. Perl and K. Banki, unpublished data. Back


   ACKNOWLEDGMENTS
 
We are grateful to Philippe Carbon (University of Strasbourg, France) for providing the ZNF143/76 N-terminal and C-terminal antibodies, Hiroshi Kubota (HSP Research Institute, Kyoto, Japan) for generously giving us the pCAGGs and pCAGGS-based ZNF143/76 expression vectors, Rolf Kletzien for providing antibody to G6PD, and Barry Knox for helpful discussions.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Cooper, R. A., and Bunn, H. F. (1991) in Harrison's Principles of Internal Medicine (Wilson, J. D., Braunwald, E., Isselbacher, K. J., Petersdorf, R. G., Martin, J. B., Fauci, A. S., and Root, R. K., eds) pp. 1531–1543, McGraw-Hill Inc., New York
  2. Mayes, P. A. (1993) in Harper's Biochemistry (Murray, R. K., Granner, D. K., Mayes, P. A., and Rodwell, V. W., eds) pp. 201–211, Appleton & Lange, East Norwalk, CT
  3. Stark, K. L., Harris, C., and Juchau, M. R. (1989) Biochem. Pharmacol. 38, 2685–2692[CrossRef][Medline] [Order article via Infotrieve]
  4. Baquer, N. Z., Hothersall, J. S., McLean, P., and Greenbaum, A. L. (1977) Dev. Med. Child Neurol. 19, 81–104[Medline] [Order article via Infotrieve]
  5. Jacobson, S. (1963) J. Comp. Neurol. 121, 5–29[CrossRef][Medline] [Order article via Infotrieve]
  6. Kelso, T. B., Shear, C. R., and Max, S. R. (1989) Am. J. Physiol. 257, E885–E894[Medline] [Order article via Infotrieve]
  7. Spolarics, Z., Bagby, G. J., Lang, C. H., and Spitzer, J. J. (1991) Biochem. J. 278, 515–519[Medline] [Order article via Infotrieve]
  8. Held, K. D., Tuttle, S. W., and Biaglow, J. E. (1993) Radiat. Res. 134, 383–389[Medline] [Order article via Infotrieve]
  9. Costa Rosa, L. F. B. P., De Almeida, A. F., Safi, D. A., and Curi, R. (1993) Physiol. Behav. 53, 651–656[CrossRef][Medline] [Order article via Infotrieve]
  10. Pilz, R. B., Willis, R. C., and Boss, G. R. (1984) J. Biol. Chem. 259, 2927–2935[Abstract/Free Full Text]
  11. Boss, G. R. (1984) J. Biol. Chem. 259, 2936–2941[Abstract/Free Full Text]
  12. Bhatnagar, A., Srivastava, S. K., and Szabo, G. (1990) Circ. Res. 67, 535–549[Abstract/Free Full Text]
  13. Tuttle, S., Varnes, M. E., Mitchell, J. B., and Biaglow, J. E. (1992) Int. J. Radiat. Oncol. Biol. Phys. 22, 671–675[Medline] [Order article via Infotrieve]
  14. Asahina, T., Kashiwagi, A., Nishio, Y., Ikebuchi, M., Harada, N., Tanaka, Y., Saeki, Y., Kikkawa, R., and Shigeta, Y. (1995) Diabetes 44, 520–526[Abstract]
  15. Kashiwagi, A., Asahina, T., Nishio, Y., Ikebuchi, M., Tanaka, Y., and Kikkawa, R. (1996) Diabetes 45, Suppl. 3, 84–86
  16. Greene, D. A., Stevens, M. J., Obrosova, I., and Feldman, E. L. (1999) Eur. J. Pharmacol. 375, 217–223[CrossRef][Medline] [Order article via Infotrieve]
  17. Thompson, C. B. (1995) Science 267, 1456–1462[Abstract/Free Full Text]
  18. Wyllie, A. H., Kerr, J. F. R., and Currie, A. E. (1980) Int. Rev. Cytol. 68, 251–306[Medline] [Order article via Infotrieve]
  19. Perl, A., Gergely, P., Jr., Puskas, F., and Banki, K. (2002) Antiox. Redox Signal. 4, 427–443[CrossRef][Medline] [Order article via Infotrieve]
  20. Horecker, B. L. (2002) J. Biol. Chem. 277, 47965–47971[Free Full Text]
  21. Wood, T. (1985) The Pentose Phosphate Pathway, Academic Press, New York
  22. Heinrich, P. C., Morris, H. P., and Weber, G. (1976) Cancer Res. 36, 3189–3197[Abstract/Free Full Text]
  23. Novello, F., and McLean, P. (1968) Biochem. J. 107, 775–791[Medline] [Order article via Infotrieve]
  24. Severin, S. E., and Stepanova, N. G. (1980) Adv. Enzyme Regul. 19, 235–255[Medline] [Order article via Infotrieve]
  25. James, H. M., Williams, S. G., Bais, R., Rofe, A. M., Edwards, J. B., and Conyers, R. A. (1985) Int. J. Vitam. Nutr. Res. 28, (suppl.) 29–46
  26. Kauffman, F. C., and Harkonen, M. H. (1977) J. Neurochem. 28, 745–750[Medline] [Order article via Infotrieve]
  27. Hothersall, J. S., Baquer, N. Z., and McLean, P. (1982) Enzyme (Basel) 27, 259–267
  28. Banki, K., Colombo, E., Sia, F., Halladay, D., Mattson, D. H., Tatum, A. H., Massa, P. T., Phillips, P. E., and Perl, A. (1994) J. Exp. Med. 180, 1649–1663[Abstract/Free Full Text]
  29. Thom, E., Mohlman, T., Quick, W. P., Camara, B., and Neuhaus, H. E. (1998) Planta 204, 226–233[CrossRef]
  30. Martin, R., McFarland, H. F., and McFarlin, D. E. (1992) Annu. Rev. Immunol. 10, 153–187[CrossRef][Medline] [Order article via Infotrieve]
  31. Merrill, J. E., Ignarro, L. J., Sherman, M. P., Melinek, J., and Lane, T. E. (1993) J. Immunol. 151, 2132–2141[Abstract]
  32. Banki, K., Hutter, E., Colombo, E., Gonchoroff, N. J., and Perl, A. (1996) J. Biol. Chem. 271, 32994–33001[Abstract/Free Full Text]
  33. Banki, K., Hutter, E., Gonchoroff, N. J., and Perl, A. (1998) J. Biol. Chem. 273, 11944–11953[Abstract/Free Full Text]
  34. Banki, K., Hutter, E., Gonchoroff, N. J., and Perl, A. (1999) J. Immunol. 162, 1466–1479[Abstract/Free Full Text]
  35. Susin, S. A., Zamzami, N., Castedo, M., Daugas, E., Wang, H. G., Geley, S., Fassy, F., Reed, J. C., and Kroemer, G. (1997) J. Exp. Med. 186, 25–37[Abstract/Free Full Text]
  36. Green, D. R., and Reed, J. C. (1998) Science 281, 1309–1312[Abstract/Free Full Text]
  37. Constantini, P., Chernyak, B. V., Petronilli, V., and Bernardi, P. (1996) J. Biol. Chem. 271, 6746–6751[Abstract/Free Full Text]
  38. Ni, T.-C., and Savageau, M. A. (1996) J. Biol. Chem. 271, 7927–7941[Abstract/Free Full Text]
  39. Ursini, M. V., Lettieri, T., Braddock, M., and Martini, G. (1993) Virology 196, 338–343[CrossRef][Medline] [Order article via Infotrieve]
  40. Banki, K., Eddy, R. L., Shows, T. B., Halladay, D. L., Bullrich, F., Croce, C. M., Jurecic, V., Baldini, A., and Perl, A. (1997) Genomics 45, 233–238[CrossRef][Medline] [Order article via Infotrieve]
  41. Banki, K., Halladay, D., and Perl, A. (1994) J. Biol. Chem. 269, 2847–2851[Abstract/Free Full Text]
  42. Perl, A., Colombo, E., Samoilova, E., Butler, M. C., and Banki, K. (2000) J. Biol. Chem. 275, 7261–7272[Abstract/Free Full Text]
  43. Myslinski, E., Krol, A., and Carbon, P. (1998) J. Biol. Chem. 273, 21998–22006[Abstract/Free Full Text]
  44. Rincon, J. C., Engler, S. K., Hargrove, B. W., and Kunkel, G. R. (1998) Nucleic Acids Res. 26, 4846–4852[Abstract/Free Full Text]
  45. Schuster, C., Myslinski, E., Krol, A., and Carbon, P. (1995) EMBO J. 14, 3777–3787[Medline] [Order article via Infotrieve]
  46. Schaub, M., Myslinski, E., Schuster, C., Krol, A., and Carbon, P. (1997) EMBO J. 16, 173–181[CrossRef][Medline] [Order article via Infotrieve]
  47. Schuster, C., Krol, A., and Carbon, P. (1998) Mol. Cell. Biol. 18, 2650–2658[Abstract/Free Full Text]
  48. Tommerup, N., and Vissing, H. (1995) Genomics 27, 259–264[CrossRef][Medline] [Order article via Infotrieve]
  49. Puskas, F., Gergely, P., Jr., Banki, K., and Perl, A. (2000) FASEB J. 14, 1352–1361[Abstract/Free Full Text]
  50. Schaub, M., Krol, A., and Carbon, P. (1999) J. Biol. Chem. 274, 24241–24249[Abstract/Free Full Text]
  51. Denny, P., Swift, S., Connor, F., and Ashworth, A. (1992) EMBO J. 11, 3705–3712[Medline] [Order article via Infotrieve]
  52. Luckow, B., and Schutz, G. (1987) Nucleic Acids Res. 15, 5490[Free Full Text]
  53. Gorman, C. M., Merlino, G. T., Willingham, M. C., Pastan, I., and Howard, B. H. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 6777–6781[Abstract/Free Full Text]
  54. Kubota, H., Yokota, S., Yanagi, H., and Yura, T. (2000) J. Biol. Chem. 275, 28641–28648[Abstract/Free Full Text]
  55. Lee, K. A., Bindereif, A., and Green, M. R. (1988) Gene Anal. Tech. 5, 22–31[CrossRef][Medline] [Order article via Infotrieve]
  56. Brenowitz, M., Senear, D. F., Shea, M. A., and Ackers, G. K. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8462–8466[Abstract/Free Full Text]
  57. Brenowitz, M., Senear, D. F., Shea, M. A., and Ackers, G. K. (1986) Methods Enzymol. 130, 132–181[Medline] [Order article via Infotrieve]
  58. Schaub, M., Myslinski, E., Krol, A., and Carbon, P. (1999) J. Biol. Chem. 274, 25042–25050[Abstract/Free Full Text]
  59. Cramer, C. T., Cooke, S., Ginsberg, L. C., Kletzien, R. F., Stapleton, S. R., and Ulrich, R. G. (1995) J. Biochem. Toxicol. 10, 293–298[Medline] [Order article via Infotrieve]
  60. Quandt, K., Frech, K., Karas, H., Wingender, E., and Werner, T. (1995) Nucleic Acids Res. 23, 4878–4884[Abstract/Free Full Text]
  61. Adachi, K., Saito, H., Tanaka, T., and Oka, T. (1998) J. Biol. Chem. 273, 8598–8606[Abstract/Free Full Text]
  62. Schaub, M., Krol, A., and Carbon, P. (2000) Nucleic Acids Res. 28, 2114–2121[Abstract/Free Full Text]
  63. Imagawa, M., Chiu, R., and Karin, M. (1987) Cell 51, 251–260[CrossRef][Medline] [Order article via Infotrieve]
  64. Williams, T., Admon, A., Luscher, B., and Tjian, R. (1988) Genes Dev. 2, 1557–1569[Abstract/Free Full Text]
  65. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene (Amst.) 108, 193–199[CrossRef][Medline] [Order article via Infotrieve]
  66. Lachaise, F., Nassar, F., Ducancel, F., Italiano, R., and Martin, G. (2002) Gene (Amst.) 299, 263–270[CrossRef][Medline] [Order article via Infotrieve]
  67. Ragoussis, J., Senger, G., Mockridge, I., Sanseau, P., Ruddy, S., Dudley, K., Sheer, D., and Trowsdale, J. (1992) Genomics 14, 673–679[CrossRef][Medline] [Order article via Infotrieve]
  68. Cabezas, H., Raposo, R. R., and Melendez-Hevia, E. (1999) Mol. Cell. Biochem. 201, 57–63[CrossRef][Medline] [Order article via Infotrieve]
  69. Kuhn, E., and Brand, K. (1972) Biochemistry 11, 1767–1772[CrossRef][Medline] [Order article via Infotrieve]
  70. Adachi, K., Tanaka, T., Saito, H., and Oka, T. (1999) Endocrinology 140, 618–623[Abstract/Free Full Text]
  71. Blake, M. C., Jambou, R. C., Swick, A. G., Kahn, J. W., and Azizkhan, J. C. (1990) Mol. Cell. Biol. 10, 6632–6641[Abstract/Free Full Text]
  72. Terzano, S., Flora, A., Clementi, F., and Fornasari, D. (2000) J. Biol. Chem. 275, 41495–41503[Abstract/Free Full Text]
  73. Xu, Y., Porntadavity, S., and St Clair, D. K. (2002) Biochem. J. 362, 401–412[CrossRef][Medline] [Order article via Infotrieve]
  74. Xu, X. M., Tang, J. L., Chen, X., Wang, L. H., and Wu, K. K. (1997) J. Biol. Chem. 272, 6943–6950[Abstract/Free Full Text]
  75. Lebeda, R. A., Johnson, S. K., and Haun, R. S. (1999) Biochim. Biophys. Acta 1445, 314–320[Medline] [Order article via Infotrieve]
  76. Korner, K., Wolfraim, L. A., Lucibello, F. C., and Muller, R. (1997) Nucleic Acids Res. 25, 4933–4939[Abstract/Free Full Text]
  77. Myslinski, E., Schuster, C., Krol, A., and Carbon, P. (1993) J. Mol. Biol. 234, 311–318[CrossRef][Medline] [Order article via Infotrieve]
  78. Mertens, P. R., Alfonso-Jaume, M. A., Steinmann, K., and Lovett, D. H. (1998) J. Biol. Chem. 273, 32957–32965[Abstract/Free Full Text]
  79. Mertens, P. R., Steinmann, K., Alfonso-Jaume, M. A., En-Nia, A., Sun, Y., and Lovett, D. H. (2002) J. Biol. Chem. 277, 24875–24882[Abstract/Free Full Text]
  80. Wu, F., and Lee, A. S. (2002) J. Cell. Biochem. 84, 699–707[CrossRef][Medline] [Order article via Infotrieve]
  81. Batsche, E., Muchardt, C., Behrens, J., Hurst, H. C., and Cremisi, C. (1998) Mol. Cell. Biol. 18, 3647–3658[Abstract/Free Full Text]
  82. Getman, D. K., Mutero, A., Inoue, K., and Taylor, P. (1995) J. Biol. Chem. 270, 23511–23519[Abstract/Free Full Text]
  83. Benson, L. Q., Coon, M. R., Krueger, L. M., Han, G. C., Sarnaik, A. A., and Wechsler, D. S. (1999) J. Biol. Chem. 274, 28794–28802[Abstract/Free Full Text]
  84. Tan, E. L., and Wood, T. (1969) Comp. Biochem. Physiol. 31, 635–643[Medline] [Order article via Infotrieve]
  85. Hue, L., and Hers, H. G. (1974) Biochem. Biophys. Res. Commun. 58, 532–539[Medline] [Order article via Infotrieve]
  86. Baquer, N. Z., McLean, P., and Greenbaum, A. L. (1975) in Normal and Pathological Development of Energy Metabolism (Hommes, F. A., and Van den Berg, C. J., eds) pp. 109–132, Academic Press, London
  87. McDougal, D. B., Jr., Schulz, D. W., Passonneau, J. V., Clark, J. R., Reynolds, M. A., and Lowry, O. H. (1961) J. Gen. Physiol. 44, 487–498[Medline] [Order article via Infotrieve]
  88. Chambers, I., Frampton, J., Goldfarb, P., Affara, N., McBain, W., and Harrison, P. R. (1986) EMBO J. 5, 1221–1227[Medline] [Order article via Infotrieve]
  89. Esworthy, R. S., Chu, F. F., Paxton, R. J., Akman, S., and Doroshow, J. H. (1991) Arch. Biochem. Biophys. 286, 330–336[CrossRef][Medline] [Order article via Infotrieve]
  90. Berry, M. J., Banu, L., and Larsen, P. R. (1991) Nature 349, 438–440[CrossRef][Medline] [Order article via Infotrieve]
  91. Yokota, S., Yanagi, H., Yura, T., and Kubota, H. (1999) J. Biol. Chem. 274, 37070–37078[Abstract/Free Full Text]
  92. Martins, R. N., Hartmann, P. E., and Stokes, G. B. (1985) Aust. J. Biol. Sci. 38, 295–303[Medline] [Order article via Infotrieve]
  93. Young, A. J., Schmotzer, W. B., and Swanson, L. V. (1990) Proc. Soc. Exp. Biol. Med. 193, 274–279[CrossRef][Medline] [Order article via Infotrieve]
  94. Franze, A., Ferrante, M. I., Fusco, F., Santoro, A., Sanzari, E., Martini, G., and Ursini, M. V. (1998) FEBS Lett. 437, 313–318[CrossRef][Medline] [Order article via Infotrieve]
  95. Salvemini, F., Franze, A., Iervolino, A., Filosa, S., Salzano, S., and Ursini, M. V. (1999) J. Biol. Chem. 274, 2750–2757[Abstract/Free Full Text]
  96. Mach, C. M., Hargrove, B. W., and Kunkel, G. R. (2002) J. Biol. Chem. 277, 4853–4858[Abstract/Free Full Text]
  97. Lowther, W. J., Moore, P. A., Carter, K. C., and Pitha, P. M. (1999) DNA Cell Biol. 18, 685–692[CrossRef][Medline] [Order article via Infotrieve]
  98. Heylbroeck, C., Balachandran, S., Servant, M. J., DeLuca, C., Barber, G. N., Lin, R., and Hiscott, J. (2000) J. Virol. 74, 3781–3792[Abstract/Free Full Text]
  99. Saur, D., Seidler, B., Paehge, H., Schusdziarra, V., and Allescher, H. D. (2002) J. Biol. Chem. 277, 25798–25814[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Stem CellsHome page
X. Chen, F. Fang, Y.-C. Liou, and H.-H. Ng
Zfp143 Regulates Nanog Through Modulation of Oct4 Binding
Stem Cells, November 1, 2008; 26(11): 2759 - 2767.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
A. Hryniewicz-Jankowska, P. K. Choudhary, and S. R. Goodman
Variation in the Monocyte Proteome
Experimental Biology and Medicine, July 1, 2007; 232(7): 967 - 976.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. Myslinski, M.-A. Gerard, A. Krol, and P. Carbon
Transcription of the human cell cycle regulated BUB1B gene requires hStaf/ZNF143
Nucleic Acids Res., May 11, 2007; 35(10): 3453 - 3464.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Myslinski, M.-A. Gerard, A. Krol, and P. Carbon
A Genome Scale Location Analysis of Human Staf/ZNF143-binding Sites Suggests a Widespread Role for Human Staf/ZNF143 in Mammalian Promoters
J. Biol. Chem., December 29, 2006; 281(52): 39953 - 39962.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Nagy, J. Ward, D. D. Mosser, A. Koncz, P. Gergely Jr., C. Stancato, Y. Qian, D. Fernandez, B. Niland, C. E. Grossman, et al.
Regulation of CD4 Expression via Recycling by HRES-1/RAB4 Controls Susceptibility to HIV Infection
J. Biol. Chem., November 10, 2006; 281(45): 34574 - 34591.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Perl, Y. Qian, K. R. Chohan, C. R. Shirley, W. Amidon, S. Banerjee, F. A. Middleton, K. L. Conkrite, M. Barcza, N. Gonchoroff, et al.
Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa
PNAS, October 3, 2006; 103(40): 14813 - 14818.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
M. L Rise, S. E Douglas, D. Sakhrani, J. Williams, K V. Ewart, M. Rise, W. S Davidson, B. F Koop, and R. H Devlin
Multiple microarray platforms utilized for hepatic gene expression profiling of GH transgenic coho salmon with and without ration restriction.
J. Mol. Endocrinol., October 1, 2006; 37(2): 259 - 282.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/13/12190    most recent
M307039200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossman, C. E.
Right arrow Articles by Perl, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossman, C. E.
Right arrow Articles by Perl, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement